Tenofovir and bone health

August 2, 2016 at 8:21 am

Current Opinion In HIV and AIDS May 2016 V.11 N.3 P.326–332

Grant, Philip M.; Cotter, Aoife G.

aDivision of Infectious Diseases; Department of Medicine; Stanford University, Palo Alto, CA, USA

bHIV Molecular Research Group, School of Medicine & Medical Science, University College Dublin

cDepartment of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland

Purpose of review

With continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more recent bone data on tenofovir alafenamide.

Recent finding

Several studies have demonstrated an approximately 1–3% greater bone mineral density loss with TDF compared with other agents. Recent studies with tenofovir alafenamide have shown improved bone (and renal) safety with similar virologic efficacy when compared to TDF.

Summary

Given these findings, TDF-containing regimens may be gradually replaced with non-TDF containing regimens for the treatment of HIV infection, especially in those at higher risk for fragility fracture.

FULL TEXT

http://journals.lww.com/co-hivandaids/Fulltext/2016/05000/Tenofovir_and_bone_health.11.aspx

PDF (CLIC in PDF)

Entry filed under: Antirretrovirales, HIV/SIDA, HIV/SIDA HAART, HIV/SIDA Trastornos Oseos, Infecciones virales, Metodos diagnosticos, Update. Tags: .

Which HIV patients should be screened for osteoporosis: an international perspective The protease inhibitors and HIV-associated bone loss


Calendar

August 2016
M T W T F S S
« Jul   Sep »
1234567
891011121314
15161718192021
22232425262728
293031  

Most Recent Posts


%d bloggers like this: